Jian Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jian Wang has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Zhifeng Wang
First Clinical Medical College, Yunnan University of Chinese Medicine
10 shared publicationsShuangfeng Xu
First Clinical Medical College, Yunnan University of Chinese Medicine
8 shared publicationsTing Shi
First Clinical Medical College, Yunnan University of Chinese Medicine
8 shared publicationsJunfeng Lan
First Clinical Medical College, Yunnan University of Chinese Medicine
7 shared publications- Liwei Xing
The First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, China
7 shared publications Jiao Yang
Second Clinical Medical Schoo, Yunnan University of Chinese Medicine, Kunming, China
6 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1924507
Neuropeptides as neuroimmune modulators in chronic wound healing: mechanistic insights and emerging therapeutic strategies
Chronic wounds, typified by diabetic foot ulcers, pressure ulcers, and venous leg ulcers, represent a major clinical challenge worldwide. Persistent inflammation associated with disrupted neuroimmune crosstalk is increasingly recognized as an important contributor to impaired chronic wound healing. Neuropeptides, including substance P, calcitonin gene-related peptide, neuropeptide Y, and vasoactive intestinal peptide, act as context-dependent neuroimmune mediators that regulate immune-cell states, inflammation resolution, angiogenesis, re-epithelialization, and extracellular-matrix remodeling through partly distinct mechanisms. This review systematically examines the molecular and cellular mechanisms through which these neuropeptides influence the chronic wound microenvironment, with particular attention to their dose-, phase-, receptor-, and cell-dependent effects. Emerging therapeutic strategies are also summarized, including conventional and stimuli-responsive hydrogels, nanoparticle–hydrogel composites, hydrogel microspheres, microneedles, electrospun scaffolds, cell-based approaches, extracellular-vesicle-based combination strategies, electrical stimulation, photobiomodulation, and anti-infective combination platforms. Most of the available evidence remains preclinical. Key translational challenges include peptide instability, receptor desensitization, wound heterogeneity, delivery-system manufacturing and standardization, and peptide-specific long-term safety. Collectively, current evidence supports neuropeptide signaling as a promising but context-dependent target for precision neuroimmune modulation in chronic wound healing.
- 2 November 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1924507
Open AccessNeuropeptides as neuroimmune modulators in chronic wound healing: mechanistic insights and emerging therapeutic strategies
Chronic wounds, typified by diabetic foot ulcers, pressure ulcers, and venous leg ulcers, represent a major clinical challenge worldwide. Persistent inflammation associated with disrupted neuroimmune crosstalk is increasingly recognized as an important contributor to impaired chronic wound healing. Neuropeptides, including substance P, calcitonin gene-related peptide, neuropeptide Y, and vasoactive intestinal peptide, act as context-dependent neuroimmune mediators that regulate immune-cell states, inflammation resolution, angiogenesis, re-epithelialization, and extracellular-matrix remodeling through partly distinct mechanisms. This review systematically examines the molecular and cellular mechanisms through which these neuropeptides influence the chronic wound microenvironment, with particular attention to their dose-, phase-, receptor-, and cell-dependent effects. Emerging therapeutic strategies are also summarized, including conventional and stimuli-responsive hydrogels, nanoparticle–hydrogel composites, hydrogel microspheres, microneedles, electrospun scaffolds, cell-based approaches, extracellular-vesicle-based combination strategies, electrical stimulation, photobiomodulation, and anti-infective combination platforms. Most of the available evidence remains preclinical. Key translational challenges include peptide instability, receptor desensitization, wound heterogeneity, delivery-system manufacturing and standardization, and peptide-specific long-term safety. Collectively, current evidence supports neuropeptide signaling as a promising but context-dependent target for precision neuroimmune modulation in chronic wound healing.
- Open Access
- 14 October 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (20) , e71381
Application of Panax notoginseng Saponins in Skin Wound Repair: Mechanisms and Research Progress
Skin wound repair involves four stages: haemostasis, inflammation, proliferation and remodelling. Refractory wounds feature prolonged healing cycles, severe scar hyperplasia and limited clinical therapeutic strategies. Panax notoginseng saponins (PNS), primarily the ginsenosides Rg1 and Rb1 monomers, display high safety and multitarget regulatory properties across the entire wound repair cycle. PNS modulates the inflammatory microenvironment and induces M2‐type polarization of macrophages by inhibiting NF‐κB, MAPK and other signalling pathways; activates the PI3K/AKT pathway to promote the proliferation and migration of keratinocytes and fibroblasts, and maintains the physiological ratio of collagen type I/III; and upregulates angiogenic factors, including VEGF and bFGF, improving local blood circulation to enhance angiogenesis. Meanwhile, it regulates collagen metabolism, blocks the TGF‐β1/Smad2/3 scar‐related pathway, and counteracts oxidative stress, thereby accelerating wound healing while inhibiting scar formation. In recent years, PNS has shown promising potential in acute trauma, diabetic foot ulcers, burns and scar repair. PLGA/chitosan nanocarriers, hydrogels, electrospun fibrous membranes and smart responsive delivery systems have effectively addressed limitations of traditional dosage forms, including low bioavailability, poor skin permeability and uneven drug release. Nevertheless, research gaps remains: unclear targets of core monomers r; ambiguous pathway interactions among monomers; and poorly understood crosstalk between signalling pathways; studies on the impacts of extraction processes on pharmacodynamic effects are lacking; and high‐level clinical evidence is inadequate. Thus, PNS possesses substantial potential for treating refractory wounds because of its multi‐component synergy and full‐cycle regulation. Future research should focus on in‐depth exploration of molecular mechanisms, standardization of extraction processes, optimization of smart delivery systems and implementation of high‐quality clinical studies to promote the translation of active ingredients from traditional Chinese medicine into modern precision therapies.
- 14 October 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (20) , e71381
Open AccessApplication of Panax notoginseng Saponins in Skin Wound Repair: Mechanisms and Research Progress
Skin wound repair involves four stages: haemostasis, inflammation, proliferation and remodelling. Refractory wounds feature prolonged healing cycles, severe scar hyperplasia and limited clinical therapeutic strategies. Panax notoginseng saponins (PNS), primarily the ginsenosides Rg1 and Rb1 monomers, display high safety and multitarget regulatory properties across the entire wound repair cycle. PNS modulates the inflammatory microenvironment and induces M2‐type polarization of macrophages by inhibiting NF‐κB, MAPK and other signalling pathways; activates the PI3K/AKT pathway to promote the proliferation and migration of keratinocytes and fibroblasts, and maintains the physiological ratio of collagen type I/III; and upregulates angiogenic factors, including VEGF and bFGF, improving local blood circulation to enhance angiogenesis. Meanwhile, it regulates collagen metabolism, blocks the TGF‐β1/Smad2/3 scar‐related pathway, and counteracts oxidative stress, thereby accelerating wound healing while inhibiting scar formation. In recent years, PNS has shown promising potential in acute trauma, diabetic foot ulcers, burns and scar repair. PLGA/chitosan nanocarriers, hydrogels, electrospun fibrous membranes and smart responsive delivery systems have effectively addressed limitations of traditional dosage forms, including low bioavailability, poor skin permeability and uneven drug release. Nevertheless, research gaps remains: unclear targets of core monomers r; ambiguous pathway interactions among monomers; and poorly understood crosstalk between signalling pathways; studies on the impacts of extraction processes on pharmacodynamic effects are lacking; and high‐level clinical evidence is inadequate. Thus, PNS possesses substantial potential for treating refractory wounds because of its multi‐component synergy and full‐cycle regulation. Future research should focus on in‐depth exploration of molecular mechanisms, standardization of extraction processes, optimization of smart delivery systems and implementation of high‐quality clinical studies to promote the translation of active ingredients from traditional Chinese medicine into modern precision therapies.
- 5 July 2026
- Published by Elsevier in Experimental Neurology
- Vol. 404, 115901
Opportunities and challenges for the application of single-cell RNA sequencing and spatial transcriptomics in ischemic stroke
- 5 July 2026
- Published by Elsevier in Experimental Neurology
- Vol. 404, 115901
Opportunities and challenges for the application of single-cell RNA sequencing and spatial transcriptomics in ischemic stroke
- 18 June 2026
- Published by Springer Nature in BioMetals
- Vol. 39 (5) , 1-24
Unveiling the pathogenesis and therapeutic strategies of Alzheimer’s disease through cuproptosis
Alzheimer’s disease (AD), a leading cause of dementia, remains incurable, necessitating novel insights into its pathogenesis and therapeutic strategies. Recent studies highlight cuproptosis—a copper (Cu)-dependent mitochondrial cell death pathway—as a critical player in AD progression. Cuproptosis is triggered by Cu overload, which disrupts mitochondrial tricarboxylic acid cycle enzymes, resulting in toxic aggregation of lipoylated proteins and iron-sulfur cluster destabilization. This process exacerbates mitochondrial dysfunction, oxidative stress, and neuronal loss, synergizing with hallmark AD pathologies like Aβ deposition and Tau hyperphosphorylation. Unlike ferroptosis or apoptosis, cuproptosis uniquely involves mitochondrial protein lipoylation and Cu homeostasis imbalance. Therapeutic strategies targeting cuproptosis include Cu chelators, inhibitors of Cu transporters, antioxidants, and gene editing approaches to restore Cu homeostasis or mitigate protein aggregation. Immunotherapy and neuroprotective agents further show promise in alleviating cuproptosis-driven neuroinflammation. Despite preclinical advancements, challenges remain in balancing Cu’s essential roles with therapeutic interventions. This review underscores cuproptosis as a pivotal mechanism in AD and outlines emerging therapeutic avenues, emphasizing the ncessity for precision in targeting Cu dysregulation to halt neurodegeneration.
- 18 June 2026
- Published by Springer Nature in BioMetals
- Vol. 39 (5) , 1-24
Unveiling the pathogenesis and therapeutic strategies of Alzheimer’s disease through cuproptosis
Alzheimer’s disease (AD), a leading cause of dementia, remains incurable, necessitating novel insights into its pathogenesis and therapeutic strategies. Recent studies highlight cuproptosis—a copper (Cu)-dependent mitochondrial cell death pathway—as a critical player in AD progression. Cuproptosis is triggered by Cu overload, which disrupts mitochondrial tricarboxylic acid cycle enzymes, resulting in toxic aggregation of lipoylated proteins and iron-sulfur cluster destabilization. This process exacerbates mitochondrial dysfunction, oxidative stress, and neuronal loss, synergizing with hallmark AD pathologies like Aβ deposition and Tau hyperphosphorylation. Unlike ferroptosis or apoptosis, cuproptosis uniquely involves mitochondrial protein lipoylation and Cu homeostasis imbalance. Therapeutic strategies targeting cuproptosis include Cu chelators, inhibitors of Cu transporters, antioxidants, and gene editing approaches to restore Cu homeostasis or mitigate protein aggregation. Immunotherapy and neuroprotective agents further show promise in alleviating cuproptosis-driven neuroinflammation. Despite preclinical advancements, challenges remain in balancing Cu’s essential roles with therapeutic interventions. This review underscores cuproptosis as a pivotal mechanism in AD and outlines emerging therapeutic avenues, emphasizing the ncessity for precision in targeting Cu dysregulation to halt neurodegeneration.
- Open Access
- 16 May 2026
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 18
Heterogeneity of Microglia in Ischemic Stroke from the Perspective of Single-Cell RNA Sequencing: Subset Characteristics, Mechanisms and Therapeutic Potential
Ischemic stroke (IS), a predominant cerebrovascular disorder contributing to global disability and mortality, characterizes by a complex, multi-tiered cascade of pathological processes. As the primary innate immune cells within the central nervous system (CNS), microglia exhibit dual functional characteristics following ischemic injury, switching dynamically between pro-inflammatory detrimental phenotypes and anti-inflammatory reparative phenotypes in response to temporal progression, cellular phenotypic transformation, and changes in the local microenvironment. Consequently, therapeutic strategies targeting microglia have garnered considerable research interest, challenging the traditional neuron-centric therapeutic approaches. Microglia display a wide range of phenotypes, and the traditional M1/M2 classification is overly simplistic, failing to capture the full spectrum of their functional diversity. In contrast, single-cell RNA sequencing (scRNA-seq) technology has surpassed the limitations of bulk sequencing, providing a robust tool for elucidating microglial heterogeneity. Recent studies utilizing animal models of stroke have identified several subsets distinct from the conventional M1/M2-like subsets, including but no limited to ischemic stroke-associated microglia (ISAM), Prdx1 + SAM, Spp1 + microglia and SAM-foamy. The mechanisms underlying microglial heterogeneity encompass innate programming influenced by genetic background, dynamic remodeling of epigenetic modifications, metabolic reprogramming in response to extrinsic microenvironmental stress, and intercellular interaction networks. This review systematically examines, from the perspective of scRNA-seq, the biological functions of MG, the heterogeneity observed throughout their CNS life cycle development and regional homeostasis, the characteristics and regulatory mechanisms of heterogeneous microglial subpopulations following ischemic stroke, and potential therapeutic strategies and associated challenges. The aim is to provide a reference for the development of precise therapeutic strategies for IS.
- 16 May 2026
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 18
Open AccessHeterogeneity of Microglia in Ischemic Stroke from the Perspective of Single-Cell RNA Sequencing: Subset Characteristics, Mechanisms and Therapeutic Potential
Ischemic stroke (IS), a predominant cerebrovascular disorder contributing to global disability and mortality, characterizes by a complex, multi-tiered cascade of pathological processes. As the primary innate immune cells within the central nervous system (CNS), microglia exhibit dual functional characteristics following ischemic injury, switching dynamically between pro-inflammatory detrimental phenotypes and anti-inflammatory reparative phenotypes in response to temporal progression, cellular phenotypic transformation, and changes in the local microenvironment. Consequently, therapeutic strategies targeting microglia have garnered considerable research interest, challenging the traditional neuron-centric therapeutic approaches. Microglia display a wide range of phenotypes, and the traditional M1/M2 classification is overly simplistic, failing to capture the full spectrum of their functional diversity. In contrast, single-cell RNA sequencing (scRNA-seq) technology has surpassed the limitations of bulk sequencing, providing a robust tool for elucidating microglial heterogeneity. Recent studies utilizing animal models of stroke have identified several subsets distinct from the conventional M1/M2-like subsets, including but no limited to ischemic stroke-associated microglia (ISAM), Prdx1 + SAM, Spp1 + microglia and SAM-foamy. The mechanisms underlying microglial heterogeneity encompass innate programming influenced by genetic background, dynamic remodeling of epigenetic modifications, metabolic reprogramming in response to extrinsic microenvironmental stress, and intercellular interaction networks. This review systematically examines, from the perspective of scRNA-seq, the biological functions of MG, the heterogeneity observed throughout their CNS life cycle development and regional homeostasis, the characteristics and regulatory mechanisms of heterogeneous microglial subpopulations following ischemic stroke, and potential therapeutic strategies and associated challenges. The aim is to provide a reference for the development of precise therapeutic strategies for IS.
- Open Access
- 1 January 2026
- Published by Wiley in Stroke Research and Treatment
- Vol. 2026 (1) , 4347247
Research Progress on the Multitarget Mechanisms of Terpenoids in the Treatment of Ischemic Stroke
Cerebral ischemic stroke (CIS) is an acute cerebrovascular disease associated with high morbidity and disability rates. It is characterized by neurological damage caused by the interruption of cerebral blood flow, often accompanied by sequelae such as motor dysfunction and cognitive decline, which seriously affect the quality of life of patients. Despite continuous advancements in treatment methods, challenges persist, such as time window constraints, limited efficacy, and potential adverse reactions. Therefore, finding more proactive and effective treatment approaches has become an urgent problem to be solved. The mechanism of action of terpenoids is not a simple single‐target inhibition. Essentially, it lies in the systematic remodeling of the postischemic neural microenvironment. The pathophysiological process of CIS involves complex cascades, including energy failure, excitotoxicity, oxidative stress, neuroinflammation, disruption of the blood–brain barrier, multiple cell death pathways, mitochondrial dysfunction, and impairment of nerve repair. Terpenoids can intervene in ischemic stroke through a dual‐mechanism approach of direct neuroprotection and indirect microenvironment regulation by targeting key nodes within the abovementioned pathological network, ultimately achieving the protection and restoration of neural function. The aim of this review was to deepen the understanding of the therapeutic value of terpenoids in stroke; from an integrated perspective, it revealed the scientific essence of the multitarget synergistic effects of natural products, thereby providing a theoretical cornerstone and an innovative direction for the development of next‐generation drugs for treating stroke.
- 1 January 2026
- Published by Wiley in Stroke Research and Treatment
- Vol. 2026 (1) , 4347247
Open AccessResearch Progress on the Multitarget Mechanisms of Terpenoids in the Treatment of Ischemic Stroke
Cerebral ischemic stroke (CIS) is an acute cerebrovascular disease associated with high morbidity and disability rates. It is characterized by neurological damage caused by the interruption of cerebral blood flow, often accompanied by sequelae such as motor dysfunction and cognitive decline, which seriously affect the quality of life of patients. Despite continuous advancements in treatment methods, challenges persist, such as time window constraints, limited efficacy, and potential adverse reactions. Therefore, finding more proactive and effective treatment approaches has become an urgent problem to be solved. The mechanism of action of terpenoids is not a simple single‐target inhibition. Essentially, it lies in the systematic remodeling of the postischemic neural microenvironment. The pathophysiological process of CIS involves complex cascades, including energy failure, excitotoxicity, oxidative stress, neuroinflammation, disruption of the blood–brain barrier, multiple cell death pathways, mitochondrial dysfunction, and impairment of nerve repair. Terpenoids can intervene in ischemic stroke through a dual‐mechanism approach of direct neuroprotection and indirect microenvironment regulation by targeting key nodes within the abovementioned pathological network, ultimately achieving the protection and restoration of neural function. The aim of this review was to deepen the understanding of the therapeutic value of terpenoids in stroke; from an integrated perspective, it revealed the scientific essence of the multitarget synergistic effects of natural products, thereby providing a theoretical cornerstone and an innovative direction for the development of next‐generation drugs for treating stroke.
- 27 November 2025
- Published by Springer Nature in Journal of Medical and Biological Engineering
- Vol. 45 (6) , 773-789
Autonomic Nervous System Adaptation to Running in a Plateau Hypoxic Environment: Mechanisms and Prospects
- 27 November 2025
- Published by Springer Nature in Journal of Medical and Biological Engineering
- Vol. 45 (6) , 773-789
Autonomic Nervous System Adaptation to Running in a Plateau Hypoxic Environment: Mechanisms and Prospects
- Open Access
- 25 November 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18 (1)
Glycolysis in polycystic ovary syndrome: pathogenesis and treatment
Polycystic ovary syndrome (PCOS) is a common gynaecological endocrine disorder that affects women of reproductive age and is often accompanied by clinical symptoms such as acne, obesity, menstrual disorders, and ovulation disorders. Although the molecular mechanisms underlying the pathophysiology of PCOS are still unknown despite the condition’s extremely complex underlying mechanism, recent studies suggest that glycolysis may be involved in PCOS pathogenesis, including hyperandrogenism, inflammation, ovulatory dysfunction, and diminished endometrial receptivity and infertility. Therefore, there is an urgent need to explore the pathogenesis and treatment of glycolysis in patients with PCOS. The present review discusses the mechanism of glycolysis, the association between glycolysis and diverse features of PCOS, the molecular mechanism underlying the involvement of glycolysis in the pathogenesis of PCOS, and some common treatment strategies involving glycolysis in patients with PCOS. More prospective studies using advanced detection technologies such as Seahorse are needed to elucidate the specific molecular mechanisms through which glycolysis is involved in the pathogenesis of PCOS.
- 25 November 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18 (1)
Open AccessGlycolysis in polycystic ovary syndrome: pathogenesis and treatment
Polycystic ovary syndrome (PCOS) is a common gynaecological endocrine disorder that affects women of reproductive age and is often accompanied by clinical symptoms such as acne, obesity, menstrual disorders, and ovulation disorders. Although the molecular mechanisms underlying the pathophysiology of PCOS are still unknown despite the condition’s extremely complex underlying mechanism, recent studies suggest that glycolysis may be involved in PCOS pathogenesis, including hyperandrogenism, inflammation, ovulatory dysfunction, and diminished endometrial receptivity and infertility. Therefore, there is an urgent need to explore the pathogenesis and treatment of glycolysis in patients with PCOS. The present review discusses the mechanism of glycolysis, the association between glycolysis and diverse features of PCOS, the molecular mechanism underlying the involvement of glycolysis in the pathogenesis of PCOS, and some common treatment strategies involving glycolysis in patients with PCOS. More prospective studies using advanced detection technologies such as Seahorse are needed to elucidate the specific molecular mechanisms through which glycolysis is involved in the pathogenesis of PCOS.
- 10 September 2025
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 25 (1) , 1-19
Key copper homeostasis genes and inflammatory mechanisms in ischemic stroke: A bioinformatics and experimental study
Ischemic stroke (IS) has high morbidity/mortality with limited treatments. This study screened core copper homeostasis-related genes in IS and validated their function as precise intervention targets. Human IS gene chip data were retrieved from GEO, and copper homeostasis genes from multiple databases. After data correction/normalization, IS differentially expressed genes (DEGs) were identified and intersected with copper genes. DAVID for GO/KEGG enrichment, STRING for PPI network, CytoHubba for key genes, and ROC curves for diagnostic value. MCAO rat models were established; after 14-day rearing, protein expression was validated via relevant assays. 1,425 IS DEGs and 2,610 copper genes intersected to 235 genes, enriched in inflammatory response, innate immunity, and TNF/NOD-like/Toll-like receptor pathways. Key genes HIF-1α, TNF, TLR4, IL-1β had IS diagnostic AUC 0.70–0.80. MCAO rats showed worse neurological deficits, larger infarcts, neuronal damage, brain copper accumulation, and upregulated key genes linked to neuroinflammation, BBB disruption, and neuronal injury. Bioinformatics and animal studies revealed copper homeostasis imbalance-related genes mediate inflammation, oxidative stress, and mitochondrial regulation, supporting the "copper accumulation–inflammation–oxidative stress" cascade. These genes may be novel IS targets. Further study on dynamic expression across ischemic time windows/brain regions and interactions with other cell death modes is needed. Graphical abstract This study used a system approach: bioinformatics screening → experimental validation → mechanism elucidation. Three cerebral ischemia datasets from GEO (GSE16561, GSE22255, GSE58294) underwent DEG analysis; Venn diagram identified core shared DEGs. GO/KEGG enrichment, STRING for PPI network, Cytoscape for hub genes, ROC curves for diagnostic potential. Rat MCAO model was established; validity verified via relevant staining; Cu2+ accumulation detected; molecular expression validated by assays.
- 10 September 2025
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 25 (1) , 1-19
Key copper homeostasis genes and inflammatory mechanisms in ischemic stroke: A bioinformatics and experimental study
Ischemic stroke (IS) has high morbidity/mortality with limited treatments. This study screened core copper homeostasis-related genes in IS and validated their function as precise intervention targets. Human IS gene chip data were retrieved from GEO, and copper homeostasis genes from multiple databases. After data correction/normalization, IS differentially expressed genes (DEGs) were identified and intersected with copper genes. DAVID for GO/KEGG enrichment, STRING for PPI network, CytoHubba for key genes, and ROC curves for diagnostic value. MCAO rat models were established; after 14-day rearing, protein expression was validated via relevant assays. 1,425 IS DEGs and 2,610 copper genes intersected to 235 genes, enriched in inflammatory response, innate immunity, and TNF/NOD-like/Toll-like receptor pathways. Key genes HIF-1α, TNF, TLR4, IL-1β had IS diagnostic AUC 0.70–0.80. MCAO rats showed worse neurological deficits, larger infarcts, neuronal damage, brain copper accumulation, and upregulated key genes linked to neuroinflammation, BBB disruption, and neuronal injury. Bioinformatics and animal studies revealed copper homeostasis imbalance-related genes mediate inflammation, oxidative stress, and mitochondrial regulation, supporting the "copper accumulation–inflammation–oxidative stress" cascade. These genes may be novel IS targets. Further study on dynamic expression across ischemic time windows/brain regions and interactions with other cell death modes is needed. Graphical abstract This study used a system approach: bioinformatics screening → experimental validation → mechanism elucidation. Three cerebral ischemia datasets from GEO (GSE16561, GSE22255, GSE58294) underwent DEG analysis; Venn diagram identified core shared DEGs. GO/KEGG enrichment, STRING for PPI network, Cytoscape for hub genes, ROC curves for diagnostic potential. Rat MCAO model was established; validity verified via relevant staining; Cu2+ accumulation detected; molecular expression validated by assays.
- Open Access
- 14 May 2025
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 36 (9) , 456-466
Effects of electroacupuncture on neural function and the expression of inflammation-related proteins NLRP3/caspase-1 in rats with ischemic stroke
This study aimed to investigate the neuroprotective effects of electroacupuncture (EA) at the Baihui and Dazhui acupoints in a rat model of ischemia-reperfusion injury. Ninety-six male Sprague–Dawley rats were randomly assigned to four groups (n = 24 per group): Sham, middle cerebral artery occlusion (MCAO), MCAO+EA, and MCAO+MCC950. The MCAO model was induced using filament embolization. Neurological function was assessed using Zea Longa scores on days 1 and 7 posttreatment, while cerebral infarction volume was measured using 2,3,5-triphenyltetrazolium chloride staining. Gene expression levels of NLRP3 and GSDMD were quantified by RT-qPCR, and protein expressions of NLRP3, GSDMD, caspase-1, IL-1β, and IL-18 were evaluated via Western blotting, immunohistochemistry, immunofluorescence staining, and ELISA. On day 1, compared with the MCAO group, the MCAO+EA and MCAO+MCC950 groups exhibited significantly reduced mRNA and protein expressions of NLRP3 and GSDMD (P < 0.05), as well as decreased levels of caspase-1, IL-1β, and IL-18 (P < 0.05). However, no significant differences were observed in neurological deficit scores or cerebral infarction volume. By day 7, both the MCAO+EA and MCAO+MCC950 groups showed significant improvements in neurological function (P < 0.05), reductions in cerebral infarction volume (P < 0.05), and further decreases in the expression of NLRP3, GSDMD, caspase-1, IL-1β, and IL-18 (P < 0.05). EA at the Baihui and Dazhui acupoints alleviates neurological deficits in ischemic stroke rats by inhibiting the NLRP3/caspase-1 inflammatory pathway and reducing the expression of apoptosis-related proteins such as NLRP3, GSDMD, caspase-1, IL-1β, and IL-18.
- 14 May 2025
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 36 (9) , 456-466
Open AccessEffects of electroacupuncture on neural function and the expression of inflammation-related proteins NLRP3/caspase-1 in rats with ischemic stroke
This study aimed to investigate the neuroprotective effects of electroacupuncture (EA) at the Baihui and Dazhui acupoints in a rat model of ischemia-reperfusion injury. Ninety-six male Sprague–Dawley rats were randomly assigned to four groups (n = 24 per group): Sham, middle cerebral artery occlusion (MCAO), MCAO+EA, and MCAO+MCC950. The MCAO model was induced using filament embolization. Neurological function was assessed using Zea Longa scores on days 1 and 7 posttreatment, while cerebral infarction volume was measured using 2,3,5-triphenyltetrazolium chloride staining. Gene expression levels of NLRP3 and GSDMD were quantified by RT-qPCR, and protein expressions of NLRP3, GSDMD, caspase-1, IL-1β, and IL-18 were evaluated via Western blotting, immunohistochemistry, immunofluorescence staining, and ELISA. On day 1, compared with the MCAO group, the MCAO+EA and MCAO+MCC950 groups exhibited significantly reduced mRNA and protein expressions of NLRP3 and GSDMD (P < 0.05), as well as decreased levels of caspase-1, IL-1β, and IL-18 (P < 0.05). However, no significant differences were observed in neurological deficit scores or cerebral infarction volume. By day 7, both the MCAO+EA and MCAO+MCC950 groups showed significant improvements in neurological function (P < 0.05), reductions in cerebral infarction volume (P < 0.05), and further decreases in the expression of NLRP3, GSDMD, caspase-1, IL-1β, and IL-18 (P < 0.05). EA at the Baihui and Dazhui acupoints alleviates neurological deficits in ischemic stroke rats by inhibiting the NLRP3/caspase-1 inflammatory pathway and reducing the expression of apoptosis-related proteins such as NLRP3, GSDMD, caspase-1, IL-1β, and IL-18.